Search Keywords:

  Sunday, October 4, 2015

North America


Middle East


South America


Past Headlines
[ All Headlines ]
HHS enhances preparedness with new products to treat severe burns    [ 10/01/2015 ]
Disaster readiness could make new treatment options available for routine burn care, mass casualties
The World Health Organization says treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at "substantial" risk    [ 9/30/2015 ]
New policies could help avert more than 21 million deaths and 28 million new infections by 2030

BiondVax Initiates a Clinical Trial in Europe for its Universal Flu Vaccine    [ 9/30/2015 ]
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial.
Children's Mercy Researchers Achieve 26-Hour Rapid Whole-Genome Sequencing In Critically Ill Infants    [ 9/30/2015 ]
New methods cut time to complete STAT-Seq test in half to accelerate diagnosis
Destroying Certain Imported Drugs: A New Rule to Protect Patients    [ 9/29/2015 ]
Recently, FDA published the final rule implementing section 708 of the Food and Drug Administration Safety and Innovation Act (FDASIA). This new rule, which will take effect on October 15, 2015, provides FDA with an administrative process for the destruction of certain drugs refused admission to the United States. Why is this important? These drugs can pose a serious public health risk to consumers in the United States.
GSK receives approval for ARNUITY™ ELLIPTA® (fluticasone furoate) in Canada for the treatment of asthma    [ 9/29/2015 ]
ARNUITY™ ELLIPTA® (fluticasone furoate dry powder for oral inhalation) has been approved in Canada as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of steroid- responsive bronchial asthma in patients aged 12 years and older.
New York Blood Center Announces New Collaboration to Foster Groundbreaking Advancements in Regenerative Medicine    [ 9/29/2015 ]
New York Blood Center (NYBC) and the Howard and Abby Milstein Foundation today announced a further expansion of their collaborative efforts to advance the use of specialized stem cell lines in regenerative medicine...
University of Michigan team helps perform first kidney transplants in Ethiopia    [ 9/29/2015 ]
A University of Michigan-led team performed the first kidney transplants in Ethiopia last week, after spending more than two years to help establish a transplant center in the African country.
Improved Adherence: MHA Specialty Pharmacy Solutions (MHA) and Barnes Precision Specialty Pharmacy Reveal Findings of Clinical Therapy Management Study    [ 9/21/2015 ]
Dr. Ness states, "The findings of improved adherence for patients who participated in the CTM's comprehensive clinical management program for immune globulin therapy at Barnes Precision Specialty Pharmacy during this study period demonstrate the CTM platform's value in addition to providing a mechanism to enhance pharmacy driven patient care and facilitate the collection of clinical metrics for specialty reporting."
FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma    [ 9/18/2015 ]
The FDA's acceptance of this new sNDA for Kyprolis follows the recent FDA approval for Kyprolis in combination with Revlimid® (lenalidomide) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination    [ 9/18/2015 ]
The researchers reported that the TXA709-cefdinir combination exhibited synergistic activity in vivo against all MRSA strains tested, with the efficacious dose of TXA709 in combination with cefdinir being reduced as much as four-fold relative to that of TXA709 alone.
Mesothelioma Website Releases Critical Information about How to Treat Mesothelioma    [ 9/18/2015 ]
As a spokesperson for noted, the founders of the site have posted the latest updates about clinical trials that are being conducted on people with mesothelioma, as well as new information about mesothelioma research.
News & Updates:

To subscribe to our weekly newsletter,
simply submit your email:


Publicity/Corporate News: Send Press Releases to mailto:
(c) 2000-2015